Roughly half of allogeneic stem cell transplant recipients who develop GVHD fail first-line steroids, and among those patients two-year survival sits at approximately 30% — a number that has barely moved despite years of second-line development. That stagnation is the real context for Cellenkos clearing FDA’s IND review for CK0802, an off-the-shelf cord blood-derived Treg therapy now authorized to enter a Phase 1b/2a trial in steroid-refractory GVHD.
The design is straightforward: multicenter, open-label, multiple infusions, with overall response rate at Day 29 as the primary endpoint. That early readout window is intentional and strategically important. Steroid-refractory GVHD moves fast, patients are fragile, and a Day 29 ORR gives the trial a decisive signal without demanding the prolonged follow-up that more immunologically complex endpoints would require. What makes CK0802 mechanistically distinct from ruxolitinib or belumosudil — the two approved second-line agents — is the claim of inflammatory resilience. Most Treg therapies lose suppressive function under the cytokine-dense conditions of active GVHD. Cellenkos argues CK0802, manufactured from neonatal cord blood units via its CRANE platform, preserves cellular naivety and retains function precisely where competitor Tregs degrade. That claim has never been tested in GVHD; it was tested in steroid-refractory COVID-19 ARDS, where a randomized trial showed an 89.7% Bayesian probability of benefit for alive-and-extubated status at Day 28. The ARDS data is encouraging but imprecise as a surrogate — cytokine storm driven by a viral pathogen and donor T-cell alloreactivity are overlapping but not identical immunological problems.
The off-the-shelf format carries real clinical weight here. Steroid-refractory GVHD demands rapid intervention; HLA-matched donor Treg products are logistically incompatible with that urgency. CK0802’s nearly three-year shelf life and immediate-use cryopreservation remove the manufacturing bottleneck that has made autologous and matched allogeneic Treg approaches impractical in this setting. Trial initiation is expected in the second half of 2026, with an early 2027 readout.
The single marker worth tracking when that readout arrives is whether ORR at Day 29 is durable enough to hold through Day 56 or Day 100 — the timepoints where current second-line therapies routinely lose their initial responses. A response that collapses at 60 days changes the entire regulatory and commercial calculus for this program.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
